酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响

doi:10.3969/j.issn.1672-5069.2021.01.020

Abstract

Abstract: Objective The aim of this study was to investigate the short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in the treatment of patients with alcoholic liver disease(ALD) and their effects on serum levels of glucose-deficient transferrin (CDT) and hepatocyte growth factor (HGF) as well as intestinal flora distribution. Methods 102 patients with ALD were admitted to the Department of Gastroenterology in our hospital between June 2018 and December 2019, and were randomly divided into control (n=51) and observation group (n=51), receiving tiopronin and metodoxine orally or liver clostridium butyricum orally at base of the two agents for 12 weeks. Serum CDT and HGF, interkeukin-6 (IL-6), tumor necrosis factor-α(TNF-α) and nuclear factor-кB (NF-кB) were detected by ELISA, and fecal bacteria flora were also detected. Results At the end of 12 week treatment, serum CDT level in the observation group was (580.2±74.2) pg/mL, significantly lower than , serum HGF level was (150.7±18.4) pg/mL, significantly lower than [(390.5±40.2) pg/mL, P<0.05] in the control; the distribution of Bifidobacterium in the observation group was (8.7±2.6) lg CFU/g, which was much higher than , that of Lactobacillus was (9.1±1.1) lg CFU/g, which was significantly higher than in the control, while the distribution of Escherichia Coli was (6.5±1.6) lg CFU/g, significantly lower than , and that of Enterococcus Faecalis was (6.8±2.0) lg CFU/g, also significantly lower than in the control; serum IL-6 level was (0.7±0.1) pg/mL, significantly lower than , serum TNF-α level was (5.2±1.6) ng/L, much lower than , and serum NF-кB level was (1.2±0.3) ng/L, significantly lower than in the control.Conclusion The application of live clostridium butyricum in assisting tiopronin and metadoxine in the treatment of patients with ALD could effectively improve intestinal flora distribution, inhibit inflammatory reaction, which might be related to the reduction of serum CDT and HGF levels.

Key words: Alcoholic Liver disease, Live clostridium butyricum, Tiopronin, Metadoxine, Sugar-deficient transferrin, Hepatocyte growth factor, Intestinal flora, Therapy

Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease[J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.

References

[1] Wang WJ, Zhao JF, Gui WF, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol, 2018, 175(3):469-484.
[2] Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67(6):2150-2166.
[3] 孙红菊, 王衍颜, 徐丛聪, 等. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究. 实用肝脏病杂志, 2020, 23(1):54-57.
[4] Li HD, Tian XL, Zhao K, et al. Effect of Clostridium butyricum in different forms on growth performance, disease resistance, expression of genes involved in immune responses and mTOR signaling pathway of Litopenaeus vannamai. Fish Shellfish Immunol, 2019, 87(1):13-21.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018更新版). 中华肝脏病杂志, 2018, 26(3):188-194.
[6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南. 实用肝脏病杂志, 2007, 1(1):4-5,3.
[7] Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest, 2017, 127(7):2829-2841.
[8] Cui YZ, Wang QJ, Chang RX, et al. Intestinal barrier function-non- alcoholic fatty liver disease interactions and possible role of gut microbiota. J Agric Food Chem, 2019, 67(10):2754-2762.
[9] Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol, 2019, 16(4):235-246.
[10] Wang M, Ma LJ, Yang Y, et al. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: a critical review. Crit Rev Food Sci Nutr, 2019, 59(1):S116-S129.
[11] Zhang P, Jia CY, Zhao YN, et al. Detection of tiopronin in body fluids and pharmaceutical products using red-emissive DNA-stabilized silver nanoclusters as a fluorescent probe. Mikrochim Acta, 2019, 186(9):609-609.
[12] Miceli DM, Gronier B. Pharmacology, systematic review and recent clinical trials of metadoxine. Rev Recent Clin Trials, 2018, 13(2):114-125.
[13] 王薇, 史林平, 石蕾, 等. 肠道益生菌辅助治疗非酒精性脂肪性肝病的临床研究. 中华内科杂志, 2018, 57(2):101-106.
[14] Isa K, Oka K, Beauchamp N, et al. Safety assessment of the clostridium butyricum MIYAIRI 588 probiotic strain including evaluation of antimicrobial sensitivity and presence of clostridium toxin genes in vitro and teratogenicity in vivo. Hum Exp Toxicol, 2016, 35(8):818-832.
[15] Hayakawa T, Masuda T, Kurosawa D, et al. Dietary administration of probiotics to sows and/or their neonates improves the reproductive performance, incidence of post-weaning diarrhea and histopathological parameters in the intestine of weaned piglets. Anim Sci J, 2016, 87(12):1501-1510.
[16] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575(7783):505-511.
[17] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016, 65(5):830-839.
[18] Arfian N, Setyaningsih WAW, Anggorowati N, et al. Ethanol extract of <i>centella asiatica</i> (gotu kola) attenuates tubular injury through inhibition of inflammatory cytokines and enhancement of anti-fibrotic factor in mice with 5/6 subtotal nephrectomy. Malays J Med Sci, 2019, 26(5):53-63.
[19] Jayakody LN, Liu JJ, Yun EJ, et al. Direct conversion of cellulose into ethanol and ethyl-β-d-glucoside via engineered saccharomyces cerevisiae. Biotechnol Bioeng, 2018, 115(12):2859-2868.
[20] Sato Y, Kuroki Y, Oka K, et al. Effects of dietary supplementation with enterococcus faecium and clostridium butyricum, either alone or in combination, on growth and fecal microbiota composition of post-weaning pigs at a commercial farm. Front Vet Sci, 2019, 6(1):26-26.
[21] Zhang SF, Tang ZS, Tong L, et al. Effects of clostridium butyricum and bifidobacterium on btla expression on cd4⁺ t cells and lymphocyte differentiation in late preterm infants. Microb Pathog, 2016, 100(1):112-118.
[22] 江舒曼, 赵寒冰, 贾林, 等. 酪酸梭菌对急性坏死性胰腺炎并发腹腔内高压大鼠肠道屏障功能及菌群的影响. 中华胰腺病杂志, 2019, 1(3):181-184.

Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[11]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[12]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[13]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.
[14]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.
[15]	Zhang Hua, Sun Baofeng, Liu Shiqi. Combination of oxaliplatin and capecitabine plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis [J]. Journal of Practical Hepatology, 2021, 24(1): 107-110.